I hereby certify that this correspondence is being filed via EFS-Web with the United States Patent and Trademark Office on August 28, 2007.

Attorney Docket No.: 022354-000310US

TOWNSEND and TOWNSEND and CREW LLP

By: bronne brown

Yvonne Mock

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Daniel GREEN et al.

Application No.: 10/540,803

Filed: December 14, 2005

For: COMPOSITIONS AND METHODS FOR THE PREVENTION AND CONTROL OF INSULIN-INDUCED

**HYPOGLYCEMIA** 

Confirmation No.: 7164

Examiner: Maury A. Audet

Art Unit: 1654

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER

37 CFR §1.97 and §1.98

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The reference cited on the attached PTO/SB/08B form are being called to the attention of the Examiner. A copy of the reference is enclosed. It is respectfully requested that the cited reference be expressly considered during the prosecution of this application, and the reference be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and reference cited is, or is considered to be

Application No.: 10/540,803

Page 2

material to patentability because it is in this statement. No inference should be made that the information and reference cited is prior art merely because it is in this statement.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Randolph Ted Apple Reg. No. 36,429

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834

Tel: 650-326-2400 Fax: 650-326-2422

RTA:ym 61099450

Substitute for form 1449B/PTO				Complete if Known	
				Application Number	10/540,803
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date Ju	June 23, 2005
				First Named Inventor	Green, Daniel T.
				Art Unit	1654
(Use as many sheets as necessary)				Examiner Name	Maury A. Audet
Sheet	1	of	1	Attorney Docket Number	022354-000310US

NON PATENT LITERATURE DOCUMENTS								
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²					
	AF	EDELMAN, "Nocturnal Administration of Very Low Dose Glucagon in Patients with Type 1 Diabetes Reduces Episodes of Nocturnal Hypoglycemia," PowerPoint Presentation at ADA 67th Scientific Sessions, June 22, 2007.						
			•••••					
	. <u>l.</u>	<u> </u>						
Examiner Signature		Date Considered						

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.